MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.91 -1.51

Buy Sell

Overview

Share price change

24h

Current

Min

3.77

Max

3.98

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+280.05% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.1M 231M
Previous open	5.42
Previous close	3.91

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 kwi 2026, 22:56 UTC

Major News Events

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 kwi 2026, 20:50 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 kwi 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 kwi 2026, 23:23 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 kwi 2026, 23:07 UTC

Earnings

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 kwi 2026, 23:02 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 kwi 2026, 22:39 UTC

Earnings

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 kwi 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 kwi 2026, 22:00 UTC

Major News Events

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 kwi 2026, 22:00 UTC

Major News Events

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 kwi 2026, 21:31 UTC

Major News Events

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 kwi 2026, 20:38 UTC

Earnings

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 kwi 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 kwi 2026, 20:13 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 kwi 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 kwi 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

280.05% upside

12 Months Forecast

Average 14.67 USD 280.05%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.